Oxygen-carrying blood substitutes: A microvascular perspective

Expert Opinion on Biological Therapy

Volumn 4, Issue 7, 2004, Pages 1147-1157

  Tsai, Amy G ^a,b   Cabrales, Pedro ^a,b   Intaglietta, Marcos ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b LA JOLLA BIOENGINEERING INSTITUTE   (United States)

Author keywords

Exchange transfusion; Microcirculation; Oxygen distribution; p50; Shock resuscitation; Viscosity

Indexed keywords

ARTIFICIAL BLOOD; BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; HYDROGEN PEROXIDE; NITRIC OXIDE; OXYGEN RADICAL; OXYGLOBIN; POLYMERIZED HEMOGLOBIN;

BINDING AFFINITY; BIOCOMPATIBILITY; BLOOD FLOW VELOCITY; BLOOD SUBSTITUTION; EXCHANGE BLOOD TRANSFUSION; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; OXYGEN TRANSPORT; RESUSCITATION; REVIEW; SHOCK; TISSUE OXYGENATION; VISCOSITY;

ANIMALS; ANOXIA; BLOOD FLOW VELOCITY; BLOOD SUBSTITUTES; BLOOD VISCOSITY; CAPILLARIES; CATTLE; DRUG CARRIERS; DRUG COMPOUNDING; EXCHANGE TRANSFUSION, WHOLE BLOOD; HEMOGLOBINS; HEMORRHAGE; HUMANS; HYPERTENSION; LIPOSOMES; MICROCIRCULATION; OXIDATIVE STRESS; OXYGEN; PARTIAL PRESSURE; REACTIVE OXYGEN SPECIES; SHOCK; VASOCONSTRICTION;

EID: 3142666846     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.7.1147     Document Type: Review

References (54)

1. AMBERSON WR, JENNINGS JJ, RHODE CM: Clinical experience with hemoglobin-saline solutions. J. Appl. Physiol. (1949) 1:6469-6489.
2. WINSLOW RM: αα-crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang. (2000) 79:1-20. Analysis of experimental evidence that was not taken into consideration in developing HemeAssist as a blood substitute that was investigated in Phase III clinical trials. This product ultimately failed in clinical testing.
3. WINSLOW RM: Alternative oxygen therapeutics: products, status of clinical trials, and future prospects. Curr. Hemat. Reports (2003) 2:503-510.
4. WINSLOW RM: Hemoglobin-based Red Cell Substitutes. Winslow RM (Ed.), The John Hopkins University Press, Baltimore, USA (1992).
5. WINSLOW RM: Blood substitutes. Curr. Opin. Hematol. (2002) 9:146-151.
6. REID TJ: Hb-based oxygen carriers: are we there yet? Transfusion (2003) 43:280-287.
7. CRETEUR J, VINCENT JL: Hemoglobin solutions. Crit. Care Med. (2003) 31:S698-S707.
8. VANDEGRIFF KD, MALAVALLI A, WOODRIDGE J, LOHMAN J, WINSLOW RM: MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion (2003) 43(4):509-516. Biochemical and biophysical characteristics of a Hb-based OCPE that is efficacious at low dosages, and which introduces a multiplying factor between the human blood supply and the final equivalent product.
9. VERONESE FM, HARRIS JM: Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. (2002) 54:453-456.
10. CRAWFORD J: Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat. Rev. (2002) 28(Suppl. A):7-11.
11. SCOTT MD, MURAD KL: Cellular camouflage: fooling the immune system with polymers. Curr. Pharm. Des. (1998) 4:423-438.
12. IWASAKI K, IWASHITA Y: Preparation and evaluation of haemoglobin- polyethylene glycol conjugated (pyridoxalated polyethylene glycol haemoglobin) as an oxygen-carrying resuscitation fluid. Artif. Organs (1986) 10:411-416.
13. CONOVER CD, MALATESTA P, LEJEUNE L, CHANG CL, SHORR RG: The effects of hemodilution with polyethylene glycol bovine hemoglobin (PEG-Hb) in a conscious porcine model. J. Investig. Med. (1996) 44:238-246.
14. DE ANGELO J: Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome. Expert Opin. Pharmacother (1999) 1:19-29.
15. ACHARYA AS, MANJULA BN, SMITH P: Hemoglobin crosslinkers. (1996).
16. 2 therapeutics. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H1411-H1419. Experimental evidence showing that low dosage of left-shifted pegylated Hb is efficacious in improving and normalising oxygen transport in the microcirculation in extreme haemodilution.
17. RUDOLPH AS: Encapsulation of hemoglobin in liposomes. In: Blood Substitutes. Physiological Basis of Efficacy. Winslow RM, Vandegriff ICD, Intaglietta M (Eds) Birkhauser, Boston, USA (1995).
18. SAKAI H, TSAI AG, KERGER H et al.: Subcutaneous microvascular responses to hemodilution with a red cell substitute consisting of polyethyleneglycol- modified vesicles encapsulating hemoglobin. J. Biomed. Mater. Res. (1998) 40:66-78.
19. SAKAI H, TAKEOKA S, WETTSTEIN R et al.: Systemic and microvascular responses to hemorrhage shock and resuscitation with Hb vesicles. Am. J. Physiol. Heart Circ. Physiol. (2002) 283: H1191-H1199.
20. CABRALES P, TSAI AG, FRANGOS JA, BRICEŃO JC, INTAGLIETTA M: Oxygen delivery and consumption in the microcirculation after extreme hemodilution with perfluorocarbons. Am. J. Physiol. Heart Circ. Physiol. (2004) (In Press).
21. INTAGLIETTA M, JOHNSON PC, WINSLOW RM: Microvascular and tissue oxygen distribution. Cardiovasc. Res. (1996) 32:632-643.
22. MIRHASHEMI S, ERTEFAI S, MESSMER K, INTAGLIETTA M: Model analysis of the enhancement of tissue oxygenation by hemodilution due to increased microvascular flow velocity. Microvasc. Res. (1987) 34:290-301.
23. TSAI AG, SAKAI H, WETTSTEIN R, KERGER H, INTAGLIETTA M: An effective blood replacement fluid that targets oxygen delivery, increases plasma viscosity and has high oxygen affinity. NATA (2004) (In Press).
24. 2, as the released oxygen becomes available at capillary level.
25. 2.
26. TSAI AG: Influence of cell-free hemoglobin on local tissue perfusion and oxygenation after acute anemia after isovolemic hemodilution. Transfusion (2001) 41(10):1290-1298.
27. 2 in severe anemia. Am. J. Physiol. Heart Circ. Physiol. (2002) 283:H92-H101.
28. 2 of skeletal muscle in vivo. Am. J. Physiol. (1999) 277:H1831-H1840.
29. DROBIN D, KJELLSTROM BT, MALM E et al.: Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J. Appl. Physiol. (2004) 96:1843-1853.
30. WETTSTEIN R, TSAI AG, ERNI D, WINSLOW RM, INTAGLIETTA M: Resuscitation with MalPEG-hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit. Care Med. (2003) 31:1824-1830.
31. PRZYBELSKI RJ, DAILY EK, BIRBAUM ML: The pressor effect of hemoglobin - good or bad? In: Advances in Blood Substitutes, Industrial Opportunities and Medical Challenges. Winslow RM, Intaglietta M, Vendergriff KD (Eds), (1997):71-85.
32. ROHLFS RJ, BRUNNER E, CHIU A et al.: Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J. Biol. Chem. (1998) 273:12128-12134. Direct demonstration that vasoactivity and the induction of hypertension is not dependent on NO scavenging, as Hb solutions with the same NO binding capacity cause a range of responses, varying from no effect on blood pressure found with pegylated Hb to a maximal increase in blood pressure found with αα-Hb.
33. DOHERTY DH, DOYLE MP, CURRY SR et al.: Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat. Biotechnol. (1998) 16:672-676. Reports that the rate of NO reaction with recombinant Hb is directly related to the level of hypertension.
34. LANCASTER JR: Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc. Natl. Acad. Sci. USA (1994) 91:8137-8141.
35. MCCARTHY MR, VANDEGRIFF KD, WINSLOW RM: The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys. Chem. (2001) 92:103-117. Experimental demonstration of the effect of facilitated diffusion and how the oxygen flux from the flowing blood into a simulated surrounding tissue changes as a function of the diffusional properties of Hb molecules. It is shown that augmented diffusion is directly related to in vivo vasoactivity, indicating that these two phenomena give rise to an autoregulatory process.
36. MATHESON B, KWANSA HE, BUCCI E, REBEL A, KOEHLER RC: Vascular response to infusions of a nonextravasating hemoglobin polymer. J. Appl. Physiol. (2002) 93:1479-1486.
37. DULING BR, BERNE RM: Longitudinal gradients in periarteriolar oxygen tension. A possible mechanism for the participation of oxygen in the local regulation of blood flow. Circ. Res. (1970) 27:669-678.
38. MANJULA BN, TSAI AG, INTAGLIETTA M et al.: Thiolation mediated, maleimide-chemistry based pegylation of Hba: design, preparation and characterization of (PEG5K)6-hba, a new non-hypertensive Hb-based oxygen carrier. Bioconjug. Chem. (2003) (In Press).
39. FRANGOS JA, HUANG TY, CLARK CB: Steady shear and step changes in shear stimulate endothelium via independent mechanisms - Superposition of transient and sustained nitric oxide production. Biochem. Biophys. Res. Comm. (1996) 224:660-665.
40. BURHOP KE, ESTEP TE: Hemoglobin induced myocardial lesions. Artif. Cells Blood Substit. Immobil. Biotechnol. (2001) 29:101. Report of myocardial lesions in primates following the administration of HemeAssist. This type of lesion has not been reported following in the use of non-vasoactive Hb solutions; therefore, it may be directly correlated with the vasoconstrictive characteristics of this material.
41. D'AGNILLO F, ALAYASH AI: Redox cycling of diaspirin crosslinked hemoglobin induces G2/M arrest and apoptosis in cultured endothelial cells. Blood (2001) 98:3315-3323. A comprehensive and updated review of the biochemical mechanisms that may be operational in the circulation upon the introduction of free Hb molecules.
42. ALAYASH AI: Oxygen therapeutics: can we tame haemoglobin? Nat. Rev. Drug Discov. (2004) 3:152-159.
43. BALDWIN AL: Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery. Am. J. Physiol. Heart Circ. Physiol. (1999) 277(46):H650-H659.
44. MENGER MD, STEINER D, MESSMER K: Microvascular ischemia-reperfusion injury in striated muscle: significance of 'no-reflow'. Am. J. Physiol. Heart Circ. Physiol. (1992) 263:H1892-H1900.
45. FRIESENECKER B, TSAI AG, INTAGLIETTA M: Capillary perfusion during ischemia reperfusion in subcutaneous connective tissue and skin muscle. Am. J. Physiol. (1994) 267(36):H2204-2212. Investigation of the effects of the experimental conditions on the analysis of microvascular function. It is shown that ischaemia-reperfusion, coupled with the use of fluorescent markers to visualise the microcirculation, yields results that are non-existent in the absence of phototoxicity. These effects are aggravated by additional negative stimuli such as tissue exposure, surgical interventions, and unusual haemodynamic conditions.
46. 2 carriers on intestinal integrity and microvascular leakage. Am. J. Physiol. Heart Circ. Physiol. (2002) 283:H1292-H1301.
47. RICHARDSON TQ, GUYTON AC: Effects of polycythemia and anemia on cardiac output and other circulatory factors. Am. J. Physiol. (1959) 197:1167-1170.
48. MESSMER K: Hemodilution. Surg. Clin. North Am. (1975) 55:659-678.
49. 2 dissociation during 4-h hemorrhagic shock in conscious hamsters. Am. J. Physiol. (1996) 270(39):H827-H836. Experimental in vivo demonstration of the direct correlation between survival and maintenance of FCD.
50. TSAI AG, FRIESENECKER B MCCARTHY M, SAKAI H, INTAGLIETTA M: Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skin fold model. Am. J. Physiol. (1998) 275:H2170-H2180. Experimental demonstration that high-viscosity plasma in extreme haemodilution maintains microvascular function and systemic conditions, an effect that is not present at an identical reduction of haematocrit (oxygen-carrying capacity) when plasma viscosity is normal.
51. BERTUGLIA S: Increased viscosity is protective for arteriolar endothelium and microvascular perfusion during severe hemodilution in hamster cheek pouch. Microvasc. Res. (2001) 61:56-63.
52. CABRALES P, TSAI AG, INTAGLIETTA M: Microvascular pressure and functional capillary density in extreme hemodilution with low and high plasma viscosity expanders. Am. J. Physiol. Heart Circ Physiol (2004) (In Press). Experimental demonstration that microvascular function and functional capillary density are directly related to the maintenance of capillary blood pressure. In extreme haemodilution, increased plasma viscosity elevates capillary pressure at reduced overall oxygen delivery. By comparison, haemodilution to the same haematocrit, but increased blood Hb following the introduction of a low-viscosity vasoactive haemoglobin solution, lowers capillary pressure and FCD.
53. DE WITT C, SCHÄFER C, VON BISMARK P, BOLZ S, POHL U: Elevation of plasma viscosity induces sustained NO-mediated dilation in the hamster cremaster microcirculation in vivo. Pflügers Arch. (1997) 434:354-361.
54. WINSLOW RM: Oxygen transport agents: a new approach to red blood cell alternatives. Transfus. Altern. Transfus. Med. (2004) 5(6):498-504.